Short Interest in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Rises By 67.6%

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totalling 67,700 shares, a growth of 67.6% from the November 30th total of 40,400 shares. Approximately 5.1% of the shares of the stock are sold short. Based on an average daily volume of 311,300 shares, the days-to-cover ratio is currently 0.2 days.

Sonoma Pharmaceuticals Stock Performance

SNOA remained flat at $2.75 on Friday. The company had a trading volume of 39,192 shares, compared to its average volume of 208,409. The firm has a 50 day simple moving average of $2.78 and a 200 day simple moving average of $1.90. Sonoma Pharmaceuticals has a 52 week low of $2.44 and a 52 week high of $9.37. The company has a market capitalization of $3.68 million, a price-to-earnings ratio of -0.55 and a beta of 1.43.

Institutional Investors Weigh In On Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC bought a new stake in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned approximately 1.08% of Sonoma Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.